A common haplotype on methylenetetrahydrofolate reductase gene modifies the effect of angiotensin-converting enzyme inhibitor on blood pressure in essential hypertension patients - A family-based association study

Clinical and Experimental Hypertension

Volumn 27, Issue 6, 2005, Pages 509-521

  Jiang, Shanqun ^a,b   Hsu, Yi Hsiang ^b   Niu, Tianhua ^b,d   Xu, Xin ^b   Xing, Houxun ^c   Chen, Changzhong ^b   Wang, Xiaobin ^e   Zhang, Yan ^b   Peng, Shaojie ^c   Xu, Xiping ^a,b,c  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c ANHUI MEDICAL UNIVERSITY   (China)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

Angiotensin converting enzyme inhibitor; Essential hypertension; Haplotype; Methylenetetrahydrofolate reductase; Pharmacogenetics

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADENINE; BENAZEPRIL; CYTOSINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THYMINE;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHINA; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG RESPONSE; ESSENTIAL HYPERTENSION; FAMILIAL DISEASE; FAMILY; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE GENE; MULTIVARIATE ANALYSIS; PHARMACOGENETICS; REGRESSION ANALYSIS; SYSTOLIC BLOOD PRESSURE;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZAZEPINES; BLOOD PRESSURE; FAMILY; FEMALE; HAPLOTYPES; HUMANS; HYPERTENSION; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 23844464118     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1081/CEH-200067686     Document Type: Article

References (48)

1. Wong PC, Hart SD, Duncia JV, Timmermans PB. Nonpeptide angiotensin II receptor antagonists. Studies with DuP 753 and EXP3174 in dogs. Eur J Pharmacol 1991; 202(3):323-330.
2. Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension 1992; 19(6 pt 2):753-757.
3. Hahn AW, Resink TJ, Scott-Burden T, Powell J, Dohi Y, Buhler FR. Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells, a novel autocrine function. Cell Regul 1990; 1(9):649-659.
4. Nagy L, Tarjan J, Samoczi M, Kovacs I, Takacs J. Effect of benazepril on endothelial function in previously untreated hypertensive patients. The Working Group of Cardiology of the Academic Committee of Veszprem, Hungary. Am J Ther 1998; 5(4):233-236.
5. Tschudi MR, Criscione L, Novosel D, Pfeiffer K, Luscher TF. Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats. Circulation 1994; 89(5):2212-2218.
6. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilatation in humans. Circulation 1997; 95(5):1119-1121.
7. Tyagi SC, Smiley LM, Mujumdar VS. Homocyst(e)ine impairs endocardial endothelial function. Can J Physiol Pharm 1999; 77(12):950-957.
8. Lim U, Cassano PA. Homocysteine and blood pressure in the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2002; 156(12):1105- 1113.
9. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland M, Kvale G. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995; 274(19):1526-1533.
10. Dinavahi R, Cossrow N, Kushner H, Falkner B. Plasma homocysteine concentration and blood pressure in young adult African Americans. Am J Hypertens 2003; 16(9 pt 1):767-770.
11. Sutton-Tyrrell K, Bostom A, Selhub J, Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 1997; 96(6):1745-1749.
12. Iso H, Moriyama Y, Sato S, Kitamura A, Tanigawa T, Yamagishi K, Imano H, Ohira T, Okamura T, Naito Y, Shimamoto T. Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese. Circulation 2004; 109(22):2766-2772.
13. van Dijk RA, Rauwerda JA, Steyn M, Twisk JW, Stehouwer CD. Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness: a 2-year, randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol 2001; 21(12):2072-2079.
14. Kang SS, Wong PW, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase-an inherited risk factor for coronary artery disease. Am J Hum Genet 1991; 48(3):536-545.
15. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10(1):111-113.
16. van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, van den Heuvel LP, Blom HJ. A second common mutation in the methylenetetrahydrofolate reductase gene, an additional risk factor for neural-tube defects? Am J Hum Genet 1998; 62(5):1044-1051.
17. Kluijtmans LA, Young IS, Boreham CA, Murray L, McMaster D, McNulty H, Strain JJ, McPartlin J, Scott JM, Whitehead AS. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood 2003; 101(7):2483-2488.
18. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93(1):7-9.
19. Friso S, Girelli D, Trabetti E, Stranieri C, Olivieri O, Tinazzi E, Martinelli N, Faccini G, Pignatti PF, Corrocher R. A1298C methylenetetrahydrofolate reductase mutation and coronary artery disease, relationships with C677T polymorphism and homocysteine/folate metabolism. Clin Exp Med 2002; 2(1):7-12.
20. Hanson NQ, Aras O, Yang F, Tsai MY. C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene, incidence and effect of combined genotypes on plasma fasting and post-methionine load homocysteine in vascular disease. Clin Chem 2001; 47(4):661-666.
21. Friedman G, Goldschmidt N, Friedlander Y, Ben-Yehuda A, Selhub J, Babaey S, Mendel M, Kidron M, Bar-On H. A common mutation A1298C in human methylenetetrahydrofolate reductase gene, association with plasma total homocysteine and folate concentrations. J Nutr 1999; 129(9):1656-1661.
22. Castro R, Rivera I, Ravasco P, Jakobs C, Blom HJ, Camilo ME, de Almeida IT. 5,10-Methylenetetrahydrofolate reductase 677C → T and 1298A → C mutations are genetic determinants of elevated homocysteine. QJM 2003; 96(4):297-303.
23. Bonaventura D, Tirapelli CR, Haddad R, Hoehr NF, Eberlin MN, De Oliveira AM. Chronic methionine load-induced hyperhomocysteinemia enhances rat carotid responsiveness for angiotensin II. Pharmacology 2004; 70(2):91-99.
24. Chao CL, Lee YT. Impairment of cerebrovascular reactivity by methionine-induced hyperhomocysteinemia and amelioration by quinapril treatment. Stroke 2000; 31(12): 2907-2911.
25. Balfour JA, Goa KL. Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure. Drugs 1991; 42(3):511-539.
26. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348(6):529-537.
27. Urano W, Taniguchi A, Yamanaka H, Tanaka E, Nakajima H, Matsuda Y, Akama H, Kitamura Y, Kamatani N. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002; 12(3):183-190.
28. Qin ZS, Niu T, Liu JS. Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms. Am J Hum Genet 2002; 71(5):1242-1247.
29. An epidemiological approach to describing risk associated with blood pressure levels. Final report of the Working Group on Risk and High Blood Pressure. Hypertension 1985; 7(4):641-651.
30. Postma CT, Dennesen PJ, de Boo T, Thien T. First dose hypotension after captopril, can it be predicted? A study of 240 patients. J Hum Hypertens 1992; 6(3):205-209.
31. Jiang S, Hsu YH, Xu X, Xing H, Chen C, Niu T, Zhang Y, Peng S, Xu X. The C677T polymorphism of the methylenetetrahydrofolate reductase gene is associated with the level of decrease on diastolic blood pressure in essential hypertension patients treated by angiotensin-converting enzyme inhibitor. Thromb Res 2004; 113(6):361-369.
32. Niu T, Struk B, Lindpaintner K. Statistical considerations for genome-wide scans: design and application of a novel software package Polymorphism. Hum Hered 2001; 52:102-109.
33. Rabinowitz D, Laird N. A unified approach to adjusting association tests for population admixture with arbitrary pedigree structure and arbitrary missing marker information. Hum Hered 2000; 50(4):211-223.
34. Horvath S, Xu X, Lake SL, Silverman EK, Weiss ST, Laird NM. Family-based tests for associating haplotypes with general phenotype data, application to asthma genetics. Genet Epidemiol 2004; 26(1):61-69.
35. Exoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotypes frequencies in a diploid population. Mol Biol Evol 1995; 12(5):921-927.
36. LDMAX, Oxford University: www.well.ox.ac.uk/asthma/gold/docs/ldmax.html.
37. Ito T, Chiku S, Inoue E, Tomita M, Morisaki T, Morisaki H, Kamatani N. Estimation of haplotype frequencies, linkage-disequilibrium measures, and combination of haplotype copies in each pool by use of pooled DNA data. Am J Hum Genet 2003; 72(2):384-398.
38. Ogino S, Wilson RB. Genotype and haplotype distributions of MTHFR677C>T and 1298A>C single nucleotide polymorphisms, a meta-analysis. J Hum Genet 2003; 48(1):1-7.
39. Weisberg IS, Jacques PF, Selhub J, Bostom AG, Chen Z, Curtis Ellison R, Eckfeldt JH, Rozen R. The 1298A → C polymorphism in methylenetetrahydrofolate reductase (MTHFR), in vitro expression and association with homocysteine. Atherosclerosis 2001; 156(2):409-415.
40. Nestel PJ, Chronopoulos A, Cehun M. Arterial stiffness is rapidly induced by raising the plasma homocysteine concentration with methionine. Atherosclerosis 2003; 171(1):83-86.
41. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, Lee ME. Promotion of vascular smooth muscle cell growth by homocysteine, a link to atherosclerosis. Proc Natl Acad Sci 1994; 91(14):6369-6373.
42. Wang H, Jiang X, Yang F, Chapman GB, Durante W, Sibinga NE, Schafer AI. Cyclin A transcriptional suppression is the major mechanism mediating homocysteine-induced endothelial cell growth inhibition. Blood 2002; 99(3):939-945.
43. Andreassi MG, Botto N. DNA damage as a new emerging risk factor in atherosclerosis. Trends Cardiovasc Med 2003; 13(7):270-275.
44. Castro R, Rivera I, Struys EA, Jansen EE, Ravasco P, Camilo ME, Blom HJ, Jakobs C, Tavares de Almeida I. Increased homocysteine and S- adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease. Clin Chem 2003; 49(8):1292-1296.
45. Szczeklik A, Sanak M, Jankowski M, Dropinski J, Czachor R, Musial J, Axenti I, Twardowska M, Brzostek T, Tendera M. Mutation A1298C of methylenetetrahydrofolate reductase: risk for early coronary disease not associated with hyperhomocysteinemia. Am J Med Genet 2001; 101(1):36-39.
46. Castro R, Rivera I, Ravasco P, Camilo ME, Jakobs C, Blom HJ, de Almeida IT. 5,10-Methylenetetrahydrofolate reductase (MTHFR) 677C → T and 1298A → C mutations are associated with DNA hypomethylation. J Med Genet 2004; 41(6):454-458.
47. Rodriguez-Esparragon F, Hernandez-Perera O, Rodriguez-Perez JC, Anabitarte A, Diaz-Cremades JM, Losada A, Fiuza D, Hernandez E, Yunis C, Ferrario CM. The effect of methylenetetrahydrofolate reductase C677T common variant on hypertensive risk is not solely explained by increased plasma homocysteine values. Clin Exp Hypertens 2003; 25(4):209-220.
48. Kohno M, Yokokawa K, Minami M, Kano H, Yasunari K, Hanehhria T, Yoshikawa J. Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Am J Med 1999; 106(5):544-549.